Nooter K - Search Results

1

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, Nooter K. Sparreboom A, et al. Among authors: nooter k. J Chromatogr B Biomed Sci Appl. 1998 Aug 7;712(1-2):225-35. doi: 10.1016/s0378-4347(98)00147-9. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9698245 Clinical Trial.

2

Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

Loos WJ, van Zomeren DM, Gelderblom H, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):99-105. doi: 10.1016/s0378-4347(01)00432-7. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 11820300

3

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Clin Cancer Res. 2002 Mar;8(3):856-62. Clin Cancer Res. 2002. PMID: 11895919

4

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

5

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Anticancer Drugs. 2002 Aug;13(7):767-75. doi: 10.1097/00001813-200208000-00012. Anticancer Drugs. 2002. PMID: 12187334

6

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: nooter k. Clin Cancer Res. 2002 Apr;8(4):1237-41. Clin Cancer Res. 2002. PMID: 11948138 Clinical Trial.

7

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Among authors: nooter k. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

8

The (ir)relevance of plasma protein binding of anticancer drugs.

Sparreboom A, Nooter K, Loos WJ, Verweij J. Sparreboom A, et al. Among authors: nooter k. Neth J Med. 2001 Oct;59(4):196-207. doi: 10.1016/s0300-2977(01)00157-7. Neth J Med. 2001. PMID: 11578795 Review.

9

Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.

Sparreboom A, Loos WJ, Nooter K, Stoter G, Verweij J. Sparreboom A, et al. Among authors: nooter k. J Chromatogr B Biomed Sci Appl. 1999 Nov 26;735(1):111-9. doi: 10.1016/s0378-4347(99)00387-4. J Chromatogr B Biomed Sci Appl. 1999. PMID: 10630896

10

Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.

Loos WJ, de Bruijn P, van Zuylen L, Verweij J, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. J Chromatogr B Biomed Sci Appl. 1999 Dec 10;735(2):293-7. doi: 10.1016/s0378-4347(99)00414-4. J Chromatogr B Biomed Sci Appl. 1999. PMID: 10670744

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results